Stock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance

Stock Track11-06

Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision to its 2025 revenue guidance.

The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the analyst estimate of $74.2 million. Despite posting its first-ever quarterly net income of $621,000, investors seemed more focused on the company's updated outlook. Xeris revised its 2025 revenue guidance to a range of $285-$290 million, down from its previous forecast, signaling potential headwinds in its growth trajectory.

While Xeris highlighted strong growth across its product portfolio, particularly for its Cushing's syndrome treatment Recorlev, which saw a 109% year-over-year increase in revenue to $37 million, the market reaction suggests concerns about the company's ability to meet long-term growth expectations. The lowered guidance, combined with the slight revenue miss, appears to have triggered a significant sell-off as investors reassess the company's near-term prospects in a competitive pharmaceutical landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120616184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120616184","market":"hk","top_or_hot":-1,"title":"Stock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance","media":"Stock Track","content":"<p>Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision to its 2025 revenue guidance.</p>\n\n<p>The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the analyst estimate of $74.2 million. Despite posting its first-ever quarterly net income of $621,000, investors seemed more focused on the company's updated outlook. Xeris revised its 2025 revenue guidance to a range of $285-$290 million, down from its previous forecast, signaling potential headwinds in its growth trajectory.</p>\n\n<p>While Xeris highlighted strong growth across its product portfolio, particularly for its Cushing's syndrome treatment Recorlev, which saw a 109% year-over-year increase in revenue to $37 million, the market reaction suggests concerns about the company's ability to meet long-term growth expectations. The lowered guidance, combined with the slight revenue miss, appears to have triggered a significant sell-off as investors reassess the company's near-term prospects in a competitive pharmaceutical landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 23:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision to its 2025 revenue guidance.</p>\n\n<p>The biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the analyst estimate of $74.2 million. Despite posting its first-ever quarterly net income of $621,000, investors seemed more focused on the company's updated outlook. Xeris revised its 2025 revenue guidance to a range of $285-$290 million, down from its previous forecast, signaling potential headwinds in its growth trajectory.</p>\n\n<p>While Xeris highlighted strong growth across its product portfolio, particularly for its Cushing's syndrome treatment Recorlev, which saw a 109% year-over-year increase in revenue to $37 million, the market reaction suggests concerns about the company's ability to meet long-term growth expectations. The lowered guidance, combined with the slight revenue miss, appears to have triggered a significant sell-off as investors reassess the company's near-term prospects in a competitive pharmaceutical landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"","article_id":"1120616184","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120616184","pubTimestamp":1762443661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"个股赛道|Xeris Pharmaceuticals暴跌16.41%Q3营收未达预期并下调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":1},"content_text":"Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision to its 2025 revenue guidance.\nThe biopharmaceutical company reported Q3 product revenue of $74.063 million, slightly missing the analyst estimate of $74.2 million. Despite posting its first-ever quarterly net income of $621,000, investors seemed more focused on the company's updated outlook. Xeris revised its 2025 revenue guidance to a range of $285-$290 million, down from its previous forecast, signaling potential headwinds in its growth trajectory.\nWhile Xeris highlighted strong growth across its product portfolio, particularly for its Cushing's syndrome treatment Recorlev, which saw a 109% year-over-year increase in revenue to $37 million, the market reaction suggests concerns about the company's ability to meet long-term growth expectations. The lowered guidance, combined with the slight revenue miss, appears to have triggered a significant sell-off as investors reassess the company's near-term prospects in a competitive pharmaceutical landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120616184","isCrawlerRequest":true}